Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (508)	11/20/2001 9:48:48 AM
From: tuck	Read Replies (2) \| Respond to of 1005

>>MADISON, Wis. and TOKYO, Nov. 20 /PRNewswire/ -- Third Wave Technologies Inc. (Nasdaq: TWTI - news) today announced that it has shipped its 66th unique Invader® product to collaborative partner BML Inc. of Tokyo, one of the largest clinical reference laboratories in Japan, for clinical validation. The products detect and quantify genetic variations in genes regulating lipid and drug metabolism, immunology and diabetes, the majority of which are based on either BML's own proprietary genetic markers or those developed in collaboration with third parties. The two companies in January announced that they had entered into a development and commercialization agreement to expand BML's pharmacogenomic and clinical testing capabilities using Third Wave's patented Invader product platform. The arrangement between Third Wave and BML includes a limited exclusivity period for product development associated with clinical applications in Japan. The 66 products were shipped as part of that ongoing collaboration, which will continue for at least two more years and is expected to be extended. New tests will continue to be shipped to BML for its internal uses, including providing clinical patient reporting, and in collaborations with third parties for research and clinical uses. The companies are also collaborating on work to reduce the amount of genomic DNA required to perform an Invader assay to less than 0.1 nanogram per genotype. ``Third Wave's partnership with BML is ahead of schedule and we are very pleased to have shipped our 66th unique Invader clinical product to them,'' said Lance Fors, Ph.D., chairman and chief executive officer of Third Wave. ``Third Wave continues to be very enthusiastic about the opportunity to collaborate with BML and the prospects it holds for a successful long-term relationship between the two companies.'' BML provides a wide-range of laboratory testing to serve all clinical and medical needs. The company serves more than 100,000 patients per day through tests performed on a proprietary automation platform. ``BML is delighted with the Invader product platform,'' said Motoyoshi Arai, president of BML. ``The Invader products BML has received as part of our continuing collaboration with Third Wave have added exceptional value to our clinical testing program.''<< snip Cheers, Tuck